摘要
目的探讨度洛西汀联合神经妥乐平对糖尿病痛性神经病变(PDPN)的疗效和安全性。方法将2012年5月-2014年10月内蒙古医科大学附属医院收治的100例糖尿病并发痛性神经病变的患者随机分为度洛西汀联合神经妥乐平组(研究组)和单用神经妥乐平组(对照组)各50例,前者给予度洛西汀联合神经妥乐平治疗,后者单用神经妥乐平治疗,疗程8周。分别于治疗前和治疗2、4、8周后进行疼痛强度简易评述量表(VRS)、数字疼痛强度量表(NRS)评定,采用焦虑自评量表(SAS)及抑郁自评量表(SDS)评定焦虑和抑郁状态,于治疗2周、8周后测定正中神经及腓肠神经传导速度。结果治疗2、4、8周后,两组VRS、NRS评分比较差异有统计学意义(P<0.05),组间SAS和SDS评分比较差异均有统计学意义(P<0.05),两组治疗8周后与治疗前感觉神经传导速度比较差异均有统计学意义(P<0.05)。结论度洛西汀联合神经妥乐平治疗PDPN的效果和安全性可能优于单用神经妥乐平。
Objective To study the efficacy and safety of duloxetine combined with neurotropin in Painful diabetic Peripheralneuropathy( PDPN). Methods 100 patients with PDPN were randomized in the Affiliated Hospital of Inner Mongolia Medical University from 2012 May to 2014 October,50 cases for duloxetine combined with neurotropin group( study group) and neurotropin group( control group) with 50 cases. The former was treated with duloxetine and neurotropin,the latter was treated with neurotropin only,both therapies lasted for 8 weeks. All patients were evaluated respectively with Verbal Rating Scale( VRS) and Numerical Rating Scale( NRS) before treatment,2 weeks,4 weeks and 8 weeks after treatment. At the same time,all were assessed the state of anxiety and depression by Self- rating Anxiety Scale( SAS) and Self- rating Depression Scale( SDS). At the 2ndand 8thweek,sensory nerve conduction velocity of median and sural nerve were tested. Results 2 weeks,4 weeks,8 weeks after treatment,both VRS and NRS had significant difference between groups( P < 0. 05). Similarly,the scores of SAS and SDS were significantly different( P < 0. 05). The sensory nerve conduction velocity was statisticaly different in both groups after 8 weeks. Conclusion About PDPN,the therapy that duloxetine combined with neurotropin maybe better than neurotropin only in efficacy and safety.
出处
《四川精神卫生》
2015年第4期317-320,共4页
Sichuan Mental Health
